ASCO GU 2023 - Results from #20

Viewing 21-40 of 190 articles

ASCO GU 2023: CaboPoint: Interim Results from a Phase 2 Study of Cabozantinib After Checkpoint Inhibitor Therapy in Patients with Advanced Renal Cell Carcinoma

ASCO GU 2023: Outcomes by IMDC Risk in the COSMIC-313 Phase 3 Trial Evaluating Cabozantinib plus Nivolumab and Ipilimumab in First-Line Advanced RCC of IMDC Intermediate or Poor Risk

ASCO GU 2023: Cabozantinib in Combination with Atezolizumab in Non-Clear Cell Renal Cell Carcinoma: Extended Follow-up Results of Cohort 10 of the COSMIC-021 Study

ASCO GU 2023: STARLITE 2: Phase 2 Study of Nivolumab plus 177lutetium-Labeled Anti–carbonic Anhydrase IX (CAIX) Monoclonal Antibody Girentuximab (177Lu-Girentuximab) in Patients with Advanced Clear Cell Renal Cell Carcinoma

ASCO GU 2023: Biomarkers of Response to Enfortumab Vedotin in Patients with Advanced Urothelial Carcinoma: Analysis of the UNITE Study

ASCO GU 2023: Cabozantinib + Nivolumab in Adult Patients with Advanced or Metastatic Renal Cell Carcinoma: A Retrospective, Non-Interventional Study in a Real-World Cohort

ASCO GU 2023: Radical Nephrectomy in Medically Underserved Patients: Selection Bias and Disparity in Surgical Health Care Delivery

ASCO GU 2023: STARLITE 1: Phase 1b/2 Study of Combination 177Lu Girentuximab plus Cabozantinib and Nivolumab in Treatment Naïve Patients with Advanced Clear Cell RCC

ASCO GU 2023: Interim Analysis of the Prospective COTRIMS (Cologne Trial of Retroperitoneal Lymphadenectomy in Metastatic Seminoma) Trial

ASCO GU 2023: Impact of Chemotherapy on Anxiety, Depression, and Suicidality Amongst Testicular Cancer Survivors

ASCO GU 2023: CaboPoint: Interim Results from a Phase 2 Study of Cabozantinib after Checkpoint Inhibitor Therapy in Patients with Advanced Renal Cell Carcinoma

ASCO GU 2023: Optimizing Survival for Patients With Muscle-Invasive Bladder Cancer

ASCO GU 2023: Next-Generation Therapies in Nonmuscle-Invasive Bladder Cancer

ASCO GU 2023: CARINA Interim Analysis: A Non-Interventional Study of Real-World Treatment Sequencing and Outcomes in Patients with Advanced Renal Cell Carcinoma Initiated on First-Line Checkpoint Inhibitor-Based Combination Therapy

ASCO GU 2023: Overall Survival and Efficacy Results of Second-Line Treatment in Patients with Metastatic Clear Cell Renal Cell Carcinoma (mRCC) Treated in the Randomized Phase II BIONIKK Trial

ASCO GU 2023: Prediction of Response to Neoadjuvant Chemotherapy of Patients with Muscle Invasive Bladder Cancer by Molecular Subtyping and Radioligand Target Quantitation: Preview of the Bladder BRIDGister

ASCO GU 2023: Impact of Race and Payer Status on the Choice of Urinary Diversion Among Patients with Localized Bladder Carcinoma Undergoing Cystectomy

ASCO GU 2023: Patient and Physician Preferences for Adjuvant Treatment of Renal Cell Carcinoma: A Discrete-Choice Experiment

ASCO GU 2023: 54: 68Ga-PSMA-11 Patients with Newly Diagnosed and Recurrent Prostate Cancer (FIREFLY Study): Preliminary Results

ASCO GU 2023: Patient-Reported Outcomes in Cisplatin-Ineligible Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin Alone or in Combination with Pembrolizumab in the Phase 1b/2 EV-103 Cohort K

1
2
3
4
5
6
7
8
9
10